1. Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts. Issue 2 (30th December 2019) Authors: Bang, Yung‐Jue; Su, Wu‐Chou; Schuler, Martin; Nam, Do‐Hyun; Lim, Wan Teck; Bauer, Todd M.; Azaro, Analia; Poon, Ronnie Tung Ping; Hong, David; Lin, Chia‐Chi; Akimov, Mikhail; Ghebremariam, Samson; Zhao, Sylvia; Giovannini, Monica; Ma, Brigette Journal: Cancer science Issue: Volume 111:Issue 2(2020) Page Start: 536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Issue 13 (24th March 2015) Authors: Seggewiss‐Bernhardt, Ruth; Bargou, Ralf C.; Goh, Yeow Tee; Stewart, A. Keith; Spencer, Andrew; Alegre, Adrian; Bladé, Joan; Ottmann, Oliver G.; Fernandez‐Ibarra, Cristina; Lu, Hong; Pain, Scott; Akimov, Mikhail; Iyer, Swaminathan Padmanabhan Journal: Cancer Issue: Volume 121:Issue 13(2015) Page Start: 2185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗